4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial.

MLA

Hoskin, Peter J., et al. “4 Gy versus 24 Gy Radiotherapy for Patients with Indolent Lymphoma (FORT): A Randomised Phase 3 Non-Inferiority Trial.” The Lancet. Oncology, vol. 15, no. 4, Apr. 2014, pp. 457–63. EBSCOhost, https://doi.org/10.1016/S1470-2045(14)70036-1.

APA

Hoskin, P. J., Kirkwood, A. A., Popova, B., Smith, P., Robinson, M., Gallop-Evans, E., Coltart, S., Illidge, T., Madhavan, K., Brammer, C., Diez, P., Jack, A., & Syndikus, I. (2014). 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. The Lancet. Oncology, 15(4), 457–463. https://doi.org/10.1016/S1470-2045(14)70036-1

Chicago

Hoskin, Peter J, Amy A Kirkwood, Bilyana Popova, Paul Smith, Martin Robinson, Eve Gallop-Evans, Stewart Coltart, et al. 2014. “4 Gy versus 24 Gy Radiotherapy for Patients with Indolent Lymphoma (FORT): A Randomised Phase 3 Non-Inferiority Trial.” The Lancet. Oncology 15 (4): 457–63. doi:10.1016/S1470-2045(14)70036-1.